Use of a truncated CCN1 promoter for cancer diagnostics, therapeutics and theranostics

US9750823B2 · kind B2 · utility

Inventors

• Paul Fisher · Scarsdale, US
• Swadesh K. Das · Richmond, US
• Rupesh Dash · Richmond, US
• Devanand Sarkar · Richmond, US
• Siddik Sarkar · Richmond, US
• Jolene Windle · Richmond, US

Key dates

• Filing date: Jun 4, 2014
• Grant date: Sep 5, 2017
• Expiry date: Jun 4, 2034

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2830/34
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Recombinant vectors in which expression of one or more elements (e.g. genes required for viral replication, detectable imaging agents, therapeutic agents, etc.) is driven by a truncated CCN 1 cancer selective promoter (tCCN1-Prom) are provided, as are cells and transgenic animals that contain such vectors. The vectors are used in cancer therapy and/or diagnostics, and the transgenic mice are used to monitor cancer progression, e.g. in screening assays.